A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a …
PJ Mease, JS Smolen, F Behrens, P Nash… - Annals of the …, 2020 - ard.bmj.com
Objectives To compare efficacy and safety of ixekizumab (IXE) to adalimumab (ADA) in
biological disease-modifying antirheumatic drug-naïve patients with both active psoriatic …
biological disease-modifying antirheumatic drug-naïve patients with both active psoriatic …
A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a …
PJ Mease, JS Smolen… - Annals of the …, 2019 - publikationen.ub.uni-frankfurt.de
Objectives: To compare efficacy and safety of ixekizumab (IXE) to adalimumab (ADA) in
biological disease-modifying antirheumatic drug-naïve patients with both active psoriatic …
biological disease-modifying antirheumatic drug-naïve patients with both active psoriatic …
A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a …
PJ Mease, JS Smolen, F Behrens, P Nash, S Liu Leage… - 2020 - publica.fraunhofer.de
Objectives: To compare efficacy and safety of ixekizumab (IXE) to adalimumab (ADA) in
biological disease-modifying antirheumatic drug-naïve patients with both active psoriatic …
biological disease-modifying antirheumatic drug-naïve patients with both active psoriatic …
[PDF][PDF] A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results …
J Philip, S Josef, B Frank, N Peter, L Soyi, L Lingnan… - 2020 - ir.librarynmu.com
Objectives To compare efficacy and safety of ixekizumab (iXe) to adalimumab (aDa) in
biological disease-modifying antirheumatic drug-naïve patients with both active psoriatic …
biological disease-modifying antirheumatic drug-naïve patients with both active psoriatic …
A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a …
PJ Mease, JS Smolen, F Behrens, P Nash… - ANNALS OF THE …, 2020 - ricerca.unich.it
Objectives To compare efficacy and safety of ixekizumab (IXE) to adalimumab (ADA) in
biological disease-modifying antirheumatic drug-naïve patients with both active psoriatic …
biological disease-modifying antirheumatic drug-naïve patients with both active psoriatic …
A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a …
P Mease, JS Smolen, F Behrens… - Annals of the …, 2020 - digitalcommons.providence.org
OBJECTIVES: To compare efficacy and safety of ixekizumab (IXE) to adalimumab (ADA) in
biological disease-modifying antirheumatic drug-naïve patients with both active psoriatic …
biological disease-modifying antirheumatic drug-naïve patients with both active psoriatic …
[HTML][HTML] A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results …
PJ Mease, JS Smolen, F Behrens, P Nash… - Annals of the …, 2020 - ncbi.nlm.nih.gov
Objectives To compare efficacy and safety of ixekizumab (IXE) to adalimumab (ADA) in
biological disease-modifying antirheumatic drug-naïve patients with both active psoriatic …
biological disease-modifying antirheumatic drug-naïve patients with both active psoriatic …
[引用][C] A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results …
PJ Mease, JS Smolen, F Behrens… - Annals of the …, 2019 - espace.library.uq.edu.au
Objectives: To compare efficacy and safety of ixekizumab (IXE) to adalimumab (ADA) in
biological disease-modifying antirheumatic drug-naïve patients with both active psoriatic …
biological disease-modifying antirheumatic drug-naïve patients with both active psoriatic …
A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a …
PJ Mease, JS Smolen, F Behrens… - Annals of the …, 2020 - eprints.whiterose.ac.uk
Objectives: To compare efficacy and safety of ixekizumab (IXE) to adalimumab (ADA) in
biological disease-modifying antirheumatic drug-naïve patients with both active psoriatic …
biological disease-modifying antirheumatic drug-naïve patients with both active psoriatic …
[PDF][PDF] A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results …
PJ Mease, JS Smolen, F Behrens, P Nash… - Annals of the …, 2019 - ard.bmj.com
Objectives To compare efficacy and safety of ixekizumab (IXE) to adalimumab (ADA) in
biological disease-modifying antirheumatic drug-naïve patients with both active psoriatic …
biological disease-modifying antirheumatic drug-naïve patients with both active psoriatic …